8-K: Aptose Biosciences Reports Promising Safety and Efficacy for Tuspetinib Triplet Therapy in Newly Diagnosed AML at EHA 2025

Aptose Biosciences announced promising safety and efficacy data from its TUSCANY Phase 1/2 clinical trial of tuspetinib triplet therapy in newly diagnosed AML patients, presented at the 2025 European Hematology Association Congress.

Summary

• Aptose Biosciences presented updated safety, response, and minimal residual disease (MRD) clinical data from its Phase 1/2 TUSCANY trial of tuspetinib (TUS) in combination with standard of care venetoclax (VEN) and azacitidine (AZA) in newly diagnosed Acute Myeloid Leukemia (AML) patients ineligible for induction chemotherapy.
• Ten newly diagnosed AML patients have been dosed across 40 mg, 80 mg, and 120 mg TUS cohorts in the TUS+VEN+AZA triplet therapy.
• At the 40 mg TUS dose level (n=4), three subjects achieved complete remissions (CRs) and were MRD-negative, including patients with FLT3-ITD, FLT3-WT, and TP53/CK mutations.
• At the 80 mg TUS dose level (n=3), all three patients (100%) achieved composite complete remissions (CR and CRi), including a TP53-mutated/CK AML patient, though it was too early for final MRD assessment.
• At the 120 mg TUS dose level (n=3), all three patients remain on therapy, with formal response and MRD assessments still too early.
• The TUS+VEN+AZA triplet therapy has been well-tolerated with no dose-limiting toxicities (DLTs) observed to date.
• TUS demonstrated activity regardless of mutation status, with MRD-negative responses achieved across diverse genetic populations, including adverse TP53 mutations and CK.
• No prolonged myelosuppression in Cycle 1 (in the absence of AML), no treatment-related deaths, QTc prolongation, CPK elevations, differentiation syndrome, or non-hematologic serious adverse events (SAEs) were reported.

Sentiment

Score: 8

Explanation: The document presents highly positive early clinical data for a novel triplet therapy in a challenging patient population (newly diagnosed AML ineligible for induction chemotherapy). The observed complete remissions, MRD negativity, and excellent safety profile across diverse mutations are very encouraging for a clinical-stage oncology company, indicating strong potential for the drug.

Positives

• The TUS+VEN+AZA triplet therapy is well-tolerated and mutation agnostic, showing activity across diverse AML populations, including those with challenging TP53-mutated/CK and FLT3-wildtype mutations.
• Achieved complete remissions (CRs) and MRD negativity in a significant portion of newly diagnosed AML patients.
• No dose-limiting toxicities (DLTs) observed across the 40 mg, 80 mg, and 120 mg TUS dose cohorts.
• No prolonged myelosuppression in Cycle 1 (in the absence of AML), no treatment-related deaths, QTc prolongation, CPK elevations, differentiation syndrome, or non-hematologic SAEs were reported.
• TUS pharmacokinetic (PK) properties are not altered by co-administration with VEN, AZA, antifungals, or food.

Risks

• Ability to obtain the capital required for research and operations and to continue as a going concern.
• Inherent risks in early-stage drug development, including demonstrating efficacy.
• Development time/cost and the regulatory approval process.
• The progress of clinical trials.
• Ability to find and enter into agreements with potential partners.
• Ability to attract and retain key personnel.
• Changing market conditions.
• Inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities.
• Unexpected manufacturing defects.

Future Outlook

The TUSCANY Phase 1/2 study is advancing with the goal of creating an improved, durable, and well-tolerated frontline therapy for newly diagnosed AML patients that is active across diverse AML populations. The company anticipates enrolling 18-24 patients by mid-late 2025 and will release additional data as it becomes available.

Management Comments

• "The TUSCANY triplet trial is well under way, and we are observing exciting activity with the addition of TUS to the VEN+AZA standard treatment." William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose.
• "The data presented today reveal complete responses across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients." William G. Rice, Ph.D.
• "TUS appears to have tremendous opportunity in the largest markets and the most challenging of AML cases." William G. Rice, Ph.D.

Industry Context

The TUS+VEN+AZA triplet therapy is being developed as a mutation-agnostic frontline therapy for newly diagnosed AML patients who are ineligible to receive induction chemotherapy. This targets a significant and mutationally diverse patient population, including those with adverse mutations like TP53, which are typically associated with poor prognoses and are challenging to treat with existing therapies. The aim is to improve upon the current standard of care (VEN+AZA) by adding tuspetinib to achieve broader activity and durability.

Comparison to Industry Standards

• The TUS+VEN+AZA triplet is being developed to create an improved frontline therapy for newly diagnosed AML patients, building upon the existing standard of care (VEN+AZA).
• Earlier APTIVATE trials of TUS as a single agent and in combination with VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations, including those with highly adverse TP53 and RAS mutations, and mutated or unmutated FLT3 genes, which are often difficult to treat with current therapies.

Stakeholder Impact

• Shareholders: Positive impact due to promising early clinical trial results, potentially enhancing company valuation and future prospects.
• Patients: Potential for a new, effective, and well-tolerated frontline treatment option for newly diagnosed AML, particularly for those ineligible for induction chemotherapy and with difficult-to-treat mutations.
• Employees: Positive impact on morale and job security due to successful drug development progress.

Next Steps

• Continue enrollment in the TUSCANY Phase 1/2 study, with anticipated enrollment of 18-24 patients by mid-late 2025.
• Release additional clinical data as it becomes available.

Key Dates

Recommendation

Keywords

Acute Myeloid Leukemia, AML, Tuspetinib, TUS, Venetoclax, Azacitidine, TUSCANY trial, Phase 1/2, Clinical Trial, Oncology, Hematology, Precision Medicine, EHA Congress, MRD negativity, Complete Remission, TP53 mutation, FLT3-wildtype, Biotechnology, Drug Development